
Morning Call, May 23


| Price and Volume | |
|---|---|
| Recent Price | 1.64 |
| 52 Week High | 2.05 |
| 52 Week Low | 0.98 |
| Avg. Daily Vol. (Mil) | 0.40 |
| Beta (3 year) | 1.94 |
| Share Related Items | |
| Mkt Cap (Mil) | 80.87 |
| Shares Out (Mil) | 49.46 |
| Float (Mil) | 40.94 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.40 |
| Current Ratio | 2.40 |
| LT Debt/ Equity | 0.15 |
| Total Debt / Equity | 0.38 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 3.17 |
| Price/Book | 8.13 |
| Price/Cash Flow | -12.00 |
| Per Share Data | |
| Earnings | -0.08 |
| Sales | 0.52 |
| Book Value | 0.20 |
| Cash Flow | -0.14 |
| Business Summary | |
|---|---|
| PharmAthene, Inc., is a biodefense company. It is engaged in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. | |
| General Information | |
| One Park Place
Suite 450 Annapolis, MD 21401 |
|
| www.pharmathene.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 57 | |
| CEO: Eric I. Richman | |
| Short Interest | |
| Current Month (Mil) | 4.16 |
| Previous Month (Mil) | 4.21 |
| Short Interest Ratio (Days) | 19.20 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -32.00 |
| Return on Investments | -61.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | -15.10 |
| Profit Margin | -27.60 |